Inna Friesen
Overview
Explore the profile of Inna Friesen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kikhney J, Friesen I, Wiesener S, Kursawe L, Loddenkemper C, Zundorf J, et al.
Lancet Microbe
. 2024 Nov;
5(12):100934.
PMID: 39491876
Background: Mycobacterium chelonae is a rare cause of infective endocarditis that is difficult to diagnose and treat. After we found M chelonae in a series of patients, we aimed to...
2.
Friesen I, Dreyer V, Klingmuller A, Zuber S, Hoffmann A, Suarez I, et al.
Euro Surveill
. 2024 Jul;
29(28).
PMID: 38994601
This report documents the case of a Ukrainian patient infected with an extensively drug-resistant (XDR) lineage 2 strain harbouring the rifampicin resistance mutation RpoB I491F. This mutation is not detected...
3.
Wetzstein N, Diricks M, Anton T, Andres S, Kuhns M, Kohl T, et al.
Genome Med
. 2024 Jul;
16(1):86.
PMID: 38982539
Background: The Mycobacterium avium complex (MAC) comprises the most frequent non-tuberculous mycobacteria (NTM) in Central Europe and currently includes twelve species. M. avium (MAV), M. intracellulare subsp. intracellulare (MINT), and...
4.
Friesen I, Saluzzo F, Groenheit R, Aubry A, Anthony R, Niemann S, et al.
Clin Microbiol Infect
. 2024 Jun;
30(9):1204-1206.
PMID: 38851424
No abstract available.
5.
Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H, et al.
Respiration
. 2024 May;
103(9):593-600.
PMID: 38810608
Based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB) in December 2022. The new recommendations and the...
6.
Trauth J, Kantelhardt V, Usenko B, Knipper M, Kuhns M, Friesen I, et al.
Eur Respir J
. 2024 Apr;
63(5).
PMID: 38636988
No abstract available.
7.
Wetzstein N, Diricks M, Andres S, Kuhns M, Marschall L, Biciusca T, et al.
ERJ Open Res
. 2024 Mar;
10(2).
PMID: 38500796
Introduction: is a slow-growing non-tuberculous mycobacterium that can cause non-tuberculous mycobacterium (NTM) pulmonary disease and extrapulmonary infections. Until now, detailed genomic and clinical characteristics, as well as possible transmission routes...
8.
Kohler N, Karakose H, Grobbel H, Hillemann D, Andres S, Konig C, et al.
Pharmaceutics
. 2023 Nov;
15(11).
PMID: 38004523
The treatment of drug-resistant relies on complex antibiotic therapy. Inadequate antibiotic exposure can lead to treatment failure, acquired drug resistance, and an increased risk of adverse events. Therapeutic drug monitoring...
9.
Otto-Knapp R, Bauer T, Brinkmann F, Feiterna-Sperling C, Friesen I, Geerdes-Fenge H, et al.
Pneumologie
. 2023 Nov;
78(1):35-46.
PMID: 37931778
In December 2022, based on the assessment of new evidence, the World Health Organization (WHO) updated its guidelines for the treatment of drug-resistant tuberculosis (TB). The evaluation of both, these...
10.
Corbett C, Finger P, Heiss-Neumann M, Bohnert J, Eder I, Eisele M, et al.
Emerg Microbes Infect
. 2023 Oct;
12(2):2276342.
PMID: 37883336
Numbers of non-tuberculous mycobacteria (NTM) pulmonary diseases (PD) have been repeatedly reported as increasing over the last decades, particularly in Europe. Sound epidemiological data are however missing for most European...